Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Alexandra T TankkaDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0000-0003-3337-5725
Yuhan ZhangMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0009-0007-2677-1451
Jaclyn M EinsteinDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0000-0002-9823-1098
Catherine J ZhouDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0009-0000-7196-5051
Vivian N PhamDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0009-0006-7995-2187
Jack T NaritomiDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0000-0001-7746-7467
Grady G NguyenDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0009-0005-0512-3522
Amaya N Mendez-MolinaMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0002-2571-2405
Zhimin HuMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0002-4997-0986
Orel MizrahiDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0000-0003-2189-5731
Mark PerelisDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0000-0001-5435-2552
Joseph SarsamSanford Stem Cell Institute, University of California San Diego, La Jolla, California.ORCID 0009-0002-7550-3035
Frederick E TanDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0000-0001-5493-2127
Dan S KaufmanSanford Stem Cell Institute, University of California San Diego, La Jolla, California.ORCID 0000-0002-2003-2494
Jing YangMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0001-8410-3549
Corina E AntalMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0002-6174-4930
Gene W YeoDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California.ORCID 0000-0002-0799-6037
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Functional RNA elements in the human genomeR01HG004659 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kevin Daniel Corbett, Eugene Wei-Ming Yeo · 2008 to 2026
$12.4M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2017 to 2021
$10.9M
Technology Development Coordinating CenterU24HG011735 · NHGRI · JACKSON LABORATORY · PI Mark D ADAMS · 2021 to 2026
$8.1M
Predoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5M
A comprehensive binding and functional map of human RNA-binding proteinsU24HG009889 · NHGRI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI GRAVELEY, BRENTON R., YEO, EUGENE WEI-MING · 2022 to 2025
$5.5M
Regulation of Tumor Invasion and Metastasis by Matrix StiffnessR01CA174869 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jing Yang · 2015 to 2026
$4.3M
STAMP technology to enable single-cell and isoform-sensitive detection of RBP sitesR01HG011864 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YEO, EUGENE WEI-MING · 2021 to 2024
$4.0M
EPHA2 Receptor Signaling in Breast Cancer MechanotransductionR01CA262794 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE, Jing Yang · 2022 to 2026
$2.9M
Ribo-STAMPEDE: novel tools for molecular profiling of brain cell typesRF1MH126719 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPPI, GIORDANO, YEO, EUGENE WEI-MING · 2022 to 2022
$2.3M
Functional interplay between Hippo and estrogen receptor ESR1R01CA268179 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jing Yang · 2022 to 2026
$2.1M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
American Cancer Society (ACS) IRG-19-230-48-IRGChan Zuckerberg Initiative (CZI) 2023-332369Gruss-Lipper Family FoundationNational Cancer Institute (NCI) P30CA023100National Cancer Institute (NCI) P30CA23100National Institutes of Health (NIH) 1S10OD025060National Institutes of Health (NIH) S10OD026929National Institutes of Health (NIH) T32CA067754NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA174869NCI NIH HHS R01 CA262794NCI NIH HHS R01 CA268179NCI NIH HHS T32 CA067754NCI NIH HHS U54 CA209891NHGRI NIH HHS R01 HG004659NHGRI NIH HHS R01 HG011864NHGRI NIH HHS U24 HG009889NHGRI NIH HHS U24 HG011735NHLBI NIH HHS F32 HL143978NIH HHS S10 OD025060NIH HHS S10 OD026929NIMH NIH HHS RF1 MH126719V Foundation for Cancer Research (VFCR) V2024-008
6 · The paper itself
Abstract
RNA-binding proteins (RBP) are important regulators of posttranscriptional gene expression. Understanding which and how RBPs promote cancer progression is crucial for cancers that lack effective targeted therapies, such as triple-negative breast cancer (TNBC). In this study, we employed both in vitro and in vivo pooled CRISPR/Cas9 screening to identify 50 RBP candidates essential for TNBC cell survival. Integrated enhanced cross-linking and immunoprecipitation and RNA sequencing analysis identified that poly(U)-binding splicing factor 60 (PUF60) drives exon inclusion within proliferation-associated transcripts that, when misspliced, induce cell cycle arrest and DNA damage. Furthermore, disrupting PUF60 interactions with 3' splice sites via a substitution in its RNA-binding domain caused widespread exon skipping, leading to downregulation of proliferation-associated mRNAs and inducing apoptosis in TNBC cells. Knockdown of PUF60 or disruption of PUF60-RNA interactions inhibited TNBC cell proliferation and shrunk tumor xenografts in multiple models. Together, these findings reveal the molecular mechanism by which PUF60 supports cancer progression. SIGNIFICANCE: Functional screening of RNA-binding proteins is an effective strategy for identifying cancer regulators that revealed PUF60-mediated splicing activity as a driver of oncogenic proliferation and a potential therapeutic target.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression. · full record | OpenQuestion